

**Haemonetics Corporation Financial Summary for the Second Quarter FYE06**  
**Consolidated Statements of Income**  
(Unaudited data in thousands, except per share data)

<b>INCOME STATEMENT</b>	10/01/05	10/02/04	% Inc/(Dec) vs prior year
<b>NET REVENUES</b>	\$100,488	\$90,923	10.5%
Gross profit	51,765	45,549	13.6
R&D	6,283	4,253	47.7
S, G & A	30,103	27,385	9.9
Operating expenses	<u>36,386</u>	<u>31,638</u>	15.0
Operating income	15,379	13,911	10.6
Interest expense	(522)	(636)	(17.9)
Interest income	1,083	502	115.7
Other income/(expense), net	<u>481</u>	<u>(69)</u>	(797.1)
Income before taxes	16,421	13,708	19.8
Tax expense	5,476	4,834	13.3
<b>NET INCOME</b>	<u><u>\$10,945</u></u>	<u><u>\$8,874</u></u>	23.3
<b>Net income per common share assuming dilution</b>	\$0.40	\$0.34	17.6%
Weighted average number of shares			
Basic	26,395	25,258	
Diluted	27,354	25,784	

<b>PROFIT MARGINS</b>			Inc/(Dec) vs prior year profit margin %
Gross profit	51.5%	50.1%	1.4
R&D	6.3%	4.7%	
S, G & A	30.0%	30.1%	
Operating income	15.3%	15.3%	0.0
Income before taxes	16.3%	15.1%	1.2
Net income	10.9%	9.8%	

**Haemonetics Corporation Financial Summary for FYE06**  
**Consolidated Statements of Income**  
(Unaudited data in thousands, except per share data)

<b>Income Statement:</b>	10/01/05	10/02/04	% Inc/(Dec) vs prior year
<b>NET REVENUES</b>	\$203,661	\$185,525	9.8%
Gross profit	106,289	92,649	14.7%
R&D	11,824	8,307	42.3%
S, G & A	60,591	55,469	9.2%
Operating expenses	72,415	63,776	13.5%
Operating income	33,874	28,873	17.3%
Interest expense	(1,063)	(1,297)	(18.0%)
Interest income	2,396	865	177.0%
Other income/(expense), net	<u>1,345</u>	<u>(301)</u>	(546.8%)
Income before taxes	36,552	28,140	29.9%
Tax expense	12,723	9,446	34.7%
<b>NET INCOME</b>	<u>\$23,829</u>	<u>\$18,694</u>	27.5%
<b>Net income per common share assuming dilution</b>	\$0.87	\$0.73	19.2%
Weighted average number of shares			
Basic	26,338	25,207	
Diluted	27,279	25,681	

<b>PROFIT MARGINS:</b>			Inc/(Dec) vs prior year profit margin %
Gross profit	52.2%	49.9%	2.3
R&D	5.8%	4.5%	
S, G & A	29.8%	29.9%	
Operating income	16.6%	15.6%	1.0
Income before taxes	17.9%	15.2%	2.7
Net income	11.7%	10.1%	

**Haemonetics Corporation Financial Summary for FYE06**

**Revenue Analysis  
(Unaudited Data in thousands)**

	Second quarter			Six Months Ended		
	10/01/05	10/02/04	% Inc/(Dec)	10/01/05	10/02/04	% Inc/(Dec)
<b>REVENUE ANALYSIS</b>						
<b>Revenues by Geography</b>						
United States	\$37,930	\$30,403	24.8	\$76,153	\$63,310	20.3
International	<u>62,558</u>	<u>60,520</u>	3.4	<u>127,508</u>	<u>122,215</u>	4.3
Net Revenues	\$100,488	\$90,923	10.5	\$203,661	\$185,525	9.8
<hr/>						
<b>Disposable Revenues by Product Family</b>						
<b>Donor:</b>						
Plasma	\$25,938	\$24,238	7.0	\$53,241	49,724	7.1
Blood Bank	32,193	33,338	(3.4)	64,883	64,107	1.2
Red Cell	<u>8,903</u>	<u>6,653</u>	33.8	<u>17,358</u>	<u>13,114</u>	32.4
	\$67,034	\$64,229	4.4	135,482	126,945	6.7
<b>Patient:</b>						
Surgical	<u>\$19,930</u>	<u>\$20,045</u>	(0.6)	<u>\$42,615</u>	<u>\$40,818</u>	4.4
Subtotal	\$86,964	\$84,274	3.2	\$178,097	\$167,763	6.2
Equipment	\$6,623	\$2,580	156.7	12,734	9,253	37.6
Misc & Service	<u>6,901</u>	<u>4,069</u>	69.6	<u>12,830</u>	<u>8,509</u>	50.8
Net Revenues	\$100,488	\$90,923	10.5	\$203,661	\$185,525	9.8

**Haemonetics Corporation Financial Summary for FYE06**  
**Consolidated Balance Sheets**  
(Data in thousands)

<b>BALANCE SHEET:</b>	Period ending				Period ending	
	Unaudited 10/01/05	04/02/05	Unaudited 10/01/05	04/02/05		
<b><u>Assets</u></b>			<b><u>Liabilities &amp; Stockholders' Equity</u></b>			
Cash & cash equivalents	\$209,981	\$185,815	S/T debt & current maturities	\$27,643	\$26,612	
Accounts receivable, net	83,409	80,719	Other current liabilities	<u>60,256</u>	<u>61,310</u>	
Inventories, net	57,581	53,088	Total current liabilities	87,899	87,922	
Other current assets	<u>28,089</u>	<u>23,989</u>	Long-term debt	18,967	19,231	
Total current assets	379,060	343,611	Other long-term liabilities	5,107	5,469	
Net PP&E	67,075	69,337	Stockholders' equity	<u>387,250</u>	<u>355,135</u>	
Other assets	53,088	54,809				
Total assets	<u>\$499,223</u>	<u>\$467,757</u>	Total liabilities & equity	<u>\$499,223</u>	<u>\$467,757</u>	